Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
CIPLA TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-23 |
TEVA PHARMA Dec-13 |
CIPLA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,185 | 3,461 | - | |
Low | Rs | 852 | 3,006 | - | |
Sales per share (Unadj.) | Rs | 281.9 | 1,986.1 | - | |
Earnings per share (Unadj.) | Rs | 35.1 | 124.1 | - | |
Cash flow per share (Unadj.) | Rs | 49.7 | 284.6 | - | |
Dividends per share (Unadj.) | Rs | 8.50 | 108.61 | - | |
Avg Dividend yield | % | 0.8 | 3.4 | 24.8% | |
Book value per share (Unadj.) | Rs | 289.2 | 2,206.2 | - | |
Shares outstanding (eoy) | m | 807.15 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 1.6 | 221.9% | |
Avg P/E ratio | x | 29.0 | 26.1 | 111.3% | |
P/CF ratio (eoy) | x | 20.5 | 11.4 | 180.6% | |
Price / Book Value ratio | x | 3.5 | 1.5 | 240.3% | |
Dividend payout | % | 24.2 | 87.5 | 27.6% | |
Avg Mkt Cap | Rs m | 822,164 | 2,742,000 | 30.0% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 38,301 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,473.2 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,340.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 227,531 | 1,684,234 | 13.5% | |
Other income | Rs m | 5,121 | 0 | - | |
Total revenues | Rs m | 232,653 | 1,684,234 | 13.8% | |
Gross profit | Rs m | 48,079 | 461,228 | 10.4% | |
Depreciation | Rs m | 11,721 | 136,138 | 8.6% | |
Interest | Rs m | 1,095 | 33,081 | 3.3% | |
Profit before tax | Rs m | 40,384 | 292,009 | 13.8% | |
Minority Interest | Rs m | 0 | 1,327 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -191,688 | -0.0% | |
Tax | Rs m | 12,029 | -3,565 | -337.4% | |
Profit after tax | Rs m | 28,355 | 105,213 | 27.0% | |
Gross profit margin | % | 21.1 | 27.4 | 77.2% | |
Effective tax rate | % | 29.8 | -1.2 | -2,439.7% | |
Net profit margin | % | 12.5 | 6.2 | 199.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 168,051 | 1,137,525 | 14.8% | |
Current liabilities | Rs m | 50,333 | 992,018 | 5.1% | |
Net working cap to sales | % | 51.7 | 8.6 | 598.9% | |
Current ratio | x | 3.3 | 1.1 | 291.2% | |
Inventory Days | Days | 73 | 91 | 80.7% | |
Debtors Days | Days | 7 | 96 | 6.8% | |
Net fixed assets | Rs m | 117,318 | 550,108 | 21.3% | |
Share capital | Rs m | 1,614 | 4,146 | 38.9% | |
Net worth | Rs m | 233,460 | 1,870,864 | 12.5% | |
Long term debt | Rs m | 0 | 861,186 | 0.0% | |
Total assets | Rs m | 290,067 | 3,849,014 | 7.5% | |
Interest coverage | x | 37.9 | 9.8 | 385.3% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.8 | 0.4 | 179.3% | |
Return on assets | % | 10.2 | 3.6 | 282.6% | |
Return on equity | % | 12.1 | 5.6 | 216.0% | |
Return on capital | % | 17.8 | 4.9 | 360.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 32,377 | 268,380 | 12.1% | |
From Investments | Rs m | -23,885 | -95,098 | 25.1% | |
From Financial Activity | Rs m | -9,583 | -321,940 | 3.0% | |
Net Cashflow | Rs m | -968 | -148,658 | 0.7% |
Compare CIPLA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare CIPLA With: S.S.ORGANICS PARNAX LAB KERALA AYURV SAKAR HEALTHCARE VILIN BIO MED
After opening the negative note, Indian share markets continued the downtrend as the session progressed and ended the day weak.